Autoimmunity in a genetic disease - A cautionary tale

New England Journal of Medicine

Volumn 363, Issue 15, 2010, Pages 1473-1475

  Moore, Melissa J ^a,b   Flotte, Terence R ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATALUREN; DYSTROPHIN; GLUCOCORTICOID; AUTOANTIBODY; EPITOPE;

ADAPTIVE IMMUNITY; ADENO ASSOCIATED VIRUS; AUTOIMMUNITY; CLINICAL TRIAL; DUCHENNE MUSCULAR DYSTROPHY; EDITORIAL; GENETIC DISORDER; GENETIC RECOMBINATION; HUMAN; PRIORITY JOURNAL; VIRAL GENE THERAPY; EXON; FRAMESHIFT MUTATION; GENE THERAPY; GENETICS; IMMUNOLOGY; MALE; MUSCULAR DYSTROPHY, DUCHENNE; SKELETAL MUSCLE; T LYMPHOCYTE; TRANSGENE;

AUTOANTIBODIES; AUTOIMMUNITY; DYSTROPHIN; EPITOPES; EXONS; FRAMESHIFT MUTATION; GENETIC THERAPY; HUMANS; MALE; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; T-LYMPHOCYTES; TRANSGENES;

EID: 77957740872     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1009056     Document Type: Editorial

References (11)

1. Maguire AM, Simonelli F, Pierce EA, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 2008;358:2240-8.
2. Cideciyan AV, Aleman TS, Boye SL, et al. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc Natl Acad Sci U S A 2008;105:15112-7.
3. Christine CW, Starr PA, Larson PS, et al. Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology 2009;73:1662-9.
4. Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 2006;12:342-7.
5. Brantly ML, Chulay JD, Wang L, et al. Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. Proc Natl Acad Sci U S A 2009;106:16363-8.
6. Mendell JR, Campbell K, Rodino-Klapac L, et al. Dystrophin immunity in Duchenne's muscular dystrophy. N Engl J Med 2010;363:1429-37.
7. Frischmeyer PA, Dietz HC. Nonsense-mediated mRNA decay in health and disease. Hum Mol Genet 1999;8:1893-900.
8. Cooper TA, Wan L, Dreyfuss G. RNA and disease. Cell 2009;136:777-93.
9. Klein CJ, Coovert DD, Bulman DE, Ray PN, Mendell JR, Burghes AH. Somatic reversion/suppression in Duchenne muscular dystrophy (DMD): evidence supporting a frame-restoring mechanism in rare dystrophin-positive fibers. Am J Hum Genet 1992;50:950-9.
10. Arechavala-Gomeza V, Kinali M, Feng L, et al. Revertant fibres and dystrophin traces in Duchenne muscular dystrophy: implication for clinical trials. Neuromuscul Disord 2010;20:295-301.
11. Lu QL, Morris GE, Wilton SD, et al. Massive idiosyncratic exon skipping corrects the nonsense mutation in dystrophic mouse muscle and produces functional revertant fibers by clonal expansion. J Cell Biol 2000;148:985-96.